Search

Your search keyword '"Garcovich, M"' showing total 70 results

Search Constraints

Start Over You searched for: Author "Garcovich, M" Remove constraint Author: "Garcovich, M" Database Unpaywall Remove constraint Database: Unpaywall
70 results on '"Garcovich, M"'

Search Results

2. T.05.4: RENAL LITHOGENIC RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES CORRELATES WITH MICROBIOTA COMPOSITION, URINARY PROFILE AND DIETARY INTAKE

3. P363 Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn’s disease treated with ustekinumab

4. P442 Renal lithogenic risk in patients with Inflammatory Bowel Diseases correlates with microbiota composition, urinary profile and dietary intake

6. Hepatocellular carcinoma with portal vein tumor thrombus: a single-center retrospective analysis

11. P.09.10 CIRRHOTIC PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY PRESENT INCREASED CEREBRAL VASCULAR RESISTANCE, WHICH REMAINS UNCHANGED AFTER MEDICAL TREATMENT

12. P.09.30 NEW DIRECT-ACTING ANTIVIRAL (DAA) THERAPY IMPACTS LIVER STIFFNESS MEASUREMENTS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION

16. P1023 OUR PRELIMINARY EXPERIENCE WITH ElastPQ SHEAR WAVE ELASTOGRAPHY TECHNIQUE AND DOPPLER INDICES IN THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS

17. P.16.9 SHORT TREATMENT WITH RIFAXIMIN IMPROVES BLOOD CEREBRAL FLOW AT TRANSCRANIAL DOPPLER AND PSYCHOMETRIC TESTS IN CIRRHOTIC PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY

18. P.16.15 FEASIBILITY AND ACCURACY OF ELASTPQ® SHEAR WAVE ELASTOGRAPHY TECHNIQUE AND DOPPLER INDICES IN THE NON-INVASIVE ASSESSEMENT OF LIVER FIBROSIS: A PRELIMINARY EXPERIENCE

23. P.18.15 CONTRAST-ENHANCED ULTRASOUND EVALUATION OF TUMOR RESPONSE TO ANTI ANGIOGENETIC TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARINOMA

25. P.11.15 IMPACT OF PORTAL VEIN THROMBOSIS ON HEPATOCELLULAR CARCINOMA TREATMENT OUTCOME. THE HEPATOCAT GROUP EXPERIENCE

26. P.13.6 TREATMENT OF PORTAL VEIN TUMOR THROMBOSIS (PVTT) CAN IMPACT SURVIVAL OF PATIENTS WITH ADVANCED HCC?

31. 1042 SHORT-TERM EVALUATION OF HEPATOCELLULAR CARCINOMA AFTER SINGLE-STEP COMBINED TREATMENT: USEFULNESS OF CONTRAST-ENHANCED ULTRASONOGRAPHY

32. 151 REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

33. P.03.17 SHORT-TERM EVALUATION OF HEPATOCELLULAR CARCINOMA AFTER SINGLE-STEP COMBINED TREATMENT: USEFULNESS OF CONTRAST-ENHANCED ULTRASONOGRAPHY

34. P.08.13 REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

36. P.04.12 NON INVASIVE EVALUATION OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS: THE ROLE OF CONTRAST ENHANCED ULTRASOUND PERFUSION IMAGING AND DOPPLER ULTRASONOGRAPHY

37. P.08.15 SYSTEMIC ENDOTHELIAL DYSFUNCTION AS A PREDICTOR OF HYPERTENSION DEVELOPMENT IN CIRRHOTIC PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) UNDERGOING THERAPY WITH SORAFENIB

38. P.08.8 LACK OF RESPONSE AND TUMOR RECURRENCE AFTER MULTIMODAL REPEATED TREATMENT

39. P.04.16 TACROLIMUS ADMINISTRATION AND LIVER DISEASE ETIOLOGY INFLUENCE THE DEVELOPMENT OF FATTY CHANGES OF THE LIVER GRAFT AFTER LIVER TRANSPLANTATION

41. F-23 Lack of response and tumor recurrence after multimodal repeated treatment for hepatocellular carcinoma similarly affect HCC patients survival. A HEPATOCAT group experience

42. F-24 Short treatment with sorafenib is associated to tumor progression in patients with hepatocellular carcinoma

47. P.1.161: HCC PERSONALIZED TREATMENT IN THE MULTIMODAL MANAGEMENT ERA: HEPATOCAT GROUP EXPERIENCE

Catalog

Books, media, physical & digital resources